At the Icahn School of Medicine at Mount Sinai, researchers have solved a problem that has long plagued one of medicine's most effective but unwieldy treatments: they've engineered a way to make fecal microbiota transplants predictable, scalable, and manufacturable. In a small but carefully controlled clinical trial, their engineered gut bacteria performed just as well as the traditional stool-based therapy for patients struggling with recurrent Clostridioides difficile infection—a serious, often debilitating condition that strikes after antibiotic treatment wipes out the gut's natural bacterial balance.
The challenge is real. Fecal microbiota transplants, or FMTs, have proven remarkably effective at restoring healthy gut bacteria in patients with severe or recurrent C. difficile infections. But they come with a fundamental problem: each donor's stool is different, making standardization impossible. Batch-to-batch variability, sourcing challenges, and the sheer indelicacy of the approach have limited how broadly these therapies can be deployed. The Mount Sinai team, led by co-senior authors Jeremiah J. Faith, Ph.D., and Dr. Ari Grinspan, decided to extract the solution from the source itself: they isolated specific bacterial strains from donor stool and grew them under controlled manufacturing conditions, creating what's called a live biotherapeutic product, or LBP.
The results, published in Nature Medicine, are striking. In a Phase Ib clinical study enrolling 18 participants across four treatment arms—low and high doses of both FMT and engineered LBP—the team found that patients receiving the engineered bacteria achieved safety and efficacy outcomes comparable to those receiving traditional fecal transplants. More remarkably, the bacterial strains delivered through both approaches durably engrafted in recipients' guts, suggesting the engineered therapy doesn't just work in theory but actually establishes itself in patients' microbiomes the way natural therapies do.
"We wanted to create a practical, scalable way to produce defined bacterial therapeutics that could be manufactured consistently and rigorously tested," Dr. Faith explained. The engineering approach means researchers know exactly which bacterial strains are in each dose. This transparency opens doors that traditional FMT cannot: better understanding of how these therapies actually work, improved safety monitoring, tighter quality control, and the possibility of manufacturing at industrial scale. Dr. Grinspan, who directs the GI Microbial Therapeutics program at Mount Sinai, notes that moving from stool-based to defined therapies allows clinicians to "better understand how these therapies work and potentially improve safety, quality control, and scalability."
The implications ripple outward. Access to FMT is currently limited by donor availability, regulatory hurdles, and logistical complexity. A standardized, manufactured alternative could democratize treatment for C. difficile, which affects tens of thousands of patients annually. The Mount Sinai platform also opens possibilities beyond infection: the team plans to develop engineered bacterial therapies for inflammatory and infectious diseases beyond C. difficile, and they intend to make the platform technology available to other researchers.
Still, the work remains early. The trial was small, and the researchers emphasize that additional studies are needed to evaluate long-term safety and efficacy. But the proof of concept is now clear: engineered microbiome therapies can match the gold standard. In doing so, they've sketched a path toward making life-changing gut bacteria therapies available to far more patients than stool-based approaches ever could reach.